Doravirine - Merck

Drug Profile

Doravirine - Merck

Alternative Names: MK-1439; MK-1439-019

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antiretrovirals; Nitriles; Pyridones; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 24 Jul 2018 Updated efficacy and adverse events data from the phase III DRIVE-FORWARD trial in HIV-1 inections presented at the 22nd International AIDS Conference (IAC-2018)
  • 01 May 2018 Preregistration for HIV-1 infections (Combination therapy, Treatment-naive) in European Union (PO) (Merck pipeline, May 2018)
  • 08 Jan 2018 Preregistration for HIV-1 infections (Combination therapy, Treatment-naive) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top